Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Influence of Silicone Oil on Nerve Fiber Layer Thickness After Pars Plana Vitrectomy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01255306
Recruitment Status : Completed
First Posted : December 7, 2010
Results First Posted : January 24, 2012
Last Update Posted : March 23, 2012
Sponsor:
Information provided by (Responsible Party):
Mia Zoric Geber, University Hospital "Sestre Milosrdnice"

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The aim of the study is to evaluate the influence of silicone oil on thickness of the retinal nerve fiber layer by using optical coherence tomography (OCT) in patients following pars plana vitrectomy.

Condition or disease Intervention/treatment
Rhegmatogenous Retinal Detachment Toxic Effect of Silicone Glaucoma Due to Silicon Oil Other: Optical coherence tomography Drug: Local medical treatment of raised intraocular pressure

Detailed Description:

The aim of the study is to evaluate the influence of silicone oil on thickness of the retinal nerve fiber layer by using optical coherence tomography (OCT) in patients following pars plana vitrectomy.

The study will include 60 patients with a temporary silicone oil tamponade who will be surgically treated with pars plana vitrectomy for rhegmatogenous retinal detachment and proliferative vitreoretinopathy. All subjects will be subdued to complete ophthalmologic examinations, measurements of the retinal nerve fiber layer thickness by an OCT examination, tests of the visual field with the use of an Octopus computed perimeter (automated static perimetry) and FDT-perimetry - both prior to the surgery, and on control visits for check-up during the postoperative period.

All results provided by postoperative examinations will be compared with one another.

The study is expected to provide data on the effect of the silicone oil on thickness of the retinal nerve fiber layer. It is also planned to show possibilities and advantages of OCT as a method of choice in the follow-up of patients with intraocular silicone oil tamponade.

Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Actual Enrollment : 60 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: The Influence of Silicone Oil on Nerve Fiber Layer Thickness After Pars Plana Vitrectomy
Study Start Date : April 2010
Actual Primary Completion Date : November 2011
Actual Study Completion Date : December 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Dietary Fiber

Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort Intervention/treatment
NO IOP
Patients without raised IOP
 Other: Optical coherence tomography

Optical coherence tomography will be performed in all study patients following pars plans vitrectomy and silicone oil tamponade. A fellow eye of each patient will serve as a control. Each patient enrolled in a study will receive 4 measurements:

  1. On 7th postoperative day
  2. On 30th postoperative day
  3. On 90th postoperative day
  4. On 180th postoperative day
Other Name: Cirrus HD OCT ( Carl Zeiss Meditec, Dublin, CA )
RAISED IOP
Patients with raised IOP
 Other: Optical coherence tomography

Optical coherence tomography will be performed in all study patients following pars plans vitrectomy and silicone oil tamponade. A fellow eye of each patient will serve as a control. Each patient enrolled in a study will receive 4 measurements:

  1. On 7th postoperative day
  2. On 30th postoperative day
  3. On 90th postoperative day
  4. On 180th postoperative day
Other Name: Cirrus HD OCT ( Carl Zeiss Meditec, Dublin, CA )

Drug: Local medical treatment of raised intraocular pressure

In patients with raised intraocular pressure following medications will be employed in order to control the intraocular pressure:

Cosopt (dorzolamide hydrochloride-timolol maleate ophthalmic solution; b.i.d.) Ganfort (Bimatoprost, timolol maleate ophthalmic solution; once daily) Alphagan (Brimonidine ophthalmic solution; b.i.d.) In patients with intraocular pressure less than 27 mmHg Alphagan will be prescribed. In patients with intraocular pressure greater than 27 mmHg either Cosopt, or Ganfort will be prescribed under the discretion of treating physician. If intraocular pressure in patients treated with either Cosopt or Ganfort does not drop under 21 mmHg, Alphagan will be added.

Other Names:
  • 1. Cosopt
  • 2. Ganfort
  • 3. Alphagan


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Evidence of Retinal Nerve Fibre Layer Thickness Change Measured by Optical Coherence Tomography [ Time Frame: 6 months ]
    Retinal nerve fiber layer thickness change measured by optical coherence tomography might be an additional parameter that could provide new insights into clinical decision making in patients with silicone oil tamponade.


Secondary Outcome Measures :
  1. Retinal Nerve Fiber Layer Thickness Change in Patients With Raised Intraocular Pressure Secondary to Silicone Oil Endotamponade [ Time Frame: 6 months ]
    To assess whether retinal nerve fiber layer thickness changes in patients with raised intraocular pressure secondary to silicone oil endotamponade.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
tertiary care clinic
Criteria

Inclusion Criteria:

- patients with rhegmatogenous retinal detachment

Exclusion Criteria:

  • preexistent glaucoma
  • previous retinal surgery
  • placement of scleral buckle during surgery
  • patients with more than 1/2 of emulsified silicone oil in anterior chamber postoperatively
  • patients who develop silicone oil keratopathy postoperatively
  • patients who develop silicone oil cataract which blocks visualization of posterior segment
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01255306


Locations
Layout table for location information
Croatia
University Department of Ophthalmology, University Hospital "Sestre milosrdnice", Vinogradska 29
Zagreb, Croatia, 10000
Sponsors and Collaborators
University Hospital "Sestre Milosrdnice"
Investigators
Layout table for investigator information
Principal Investigator: Mia Zoric Geber, MD University department of Ophthalmology, University Hospital "Sestre milosrdnice"
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Mia Zoric Geber, Mia Zoric Geber, MD, University Hospital "Sestre Milosrdnice"
ClinicalTrials.gov Identifier: NCT01255306    
Other Study ID Numbers: KBSM-30-1/10
First Posted: December 7, 2010    Key Record Dates
Results First Posted: January 24, 2012
Last Update Posted: March 23, 2012
Last Verified: March 2012
Keywords provided by Mia Zoric Geber, University Hospital "Sestre Milosrdnice":
Rhegmatogenous retinal detachment
Pars plana vitrectomy
Silicone oil
Retinal nerve fibre layer
Additional relevant MeSH terms:
Layout table for MeSH terms
Retinal Detachment
Eye Diseases
Retinal Diseases
Brimonidine Tartrate
Antihypertensive Agents
Adrenergic alpha-2 Receptor Agonists
 Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs